Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2024
Reporting Period: Specific event date (December 19, 2024)
This filing reports the Board of Directors' approval and adoption of an updated Code of Ethics and Business Conduct. The document does not cover a standard financial reporting period (e.g., quarterly or annual results).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and focuses solely on corporate governance updates.
Material Changes
Code of Ethics Update: On December 19, 2024, the Board approved an updated Code of Ethics and Business Conduct applicable to all employees, directors, and contract workers. Key changes include:
- Clarification of reporting channels for employees and directors.
- Definition of potential consequences for violations.
- Additional guidance on avoiding conflicts of interest.
- Enhanced instructions on complying with applicable laws and regulations.
The filing explicitly states that amending the Code did not result in a waiver or implicit waiver of the previous Code.
Guidance, Outlook, and Risks
Management Commentary: The updated Code will be posted in the Investor Relations section of the company's website (https://ir.supernus.com) as soon as practicable.
Risks and Contingencies: No specific financial risks, contingencies, or unusual items are disclosed in this filing. The document contains no forward-looking guidance regarding financial performance or operational outlook.
Investor Verification Checklist
- Verify the full text of the updated Code of Ethics and Business Conduct attached as Exhibit 14.1.
- Confirm the posting of the updated Code on the company's Investor Relations website.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.